Onco Wiki / drapeau rouge

DLBCL avec indice de pronostic international 2-3 (risque intermédiaire) — ouvre la discussion sur le MDT...

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

Origine du drapeau rouge

Logique de déclenchement

{
  "any_of": [
    {
      "all_of": [
        {
          "comparator": ">=",
          "finding": "ipi_score",
          "threshold": 2
        },
        {
          "comparator": "<=",
          "finding": "ipi_score",
          "threshold": 3
        }
      ]
    },
    {
      "finding": "ipi_risk_group",
      "value": "intermediate"
    },
    {
      "finding": "ipi_risk_group",
      "value": "intermediate_low"
    },
    {
      "finding": "ipi_risk_group",
      "value": "intermediate_high"
    }
  ],
  "type": "composite_score"
}

Notes

IPI 2-3 cohort accounts for ~40% of newly-diagnosed DLBCL; POLARIX HR for PFS favored Pola-R-CHP in IPI ≥2 overall (HR 0.73) but the benefit was concentrated in IPI 3-5 / non-GCB / age >60 subgroups. ESMO 2024 frames IPI 2-3 as MDT discussion: R-CHOP-21 × 6 remains acceptable when access to polatuzumab is constrained (Ukraine: not НСЗУ-reimbursed). Direction `investigate` because flag surfaces the decision for the MDT brief but does not auto-shift indication — RF-DLBCL-HIGH-IPI (≥2 also fires) takes precedence in the engine.

Utilisé par

Algorithmes

• ALGO-DLBCL-1L - ALGO-DLBCL-1L